Characterization of a neutralizing anti-human galectin-1 monoclonal antibody with angioregulatory and immunomodulatory activities

被引：0

作者：

Juan M. Pérez Sáez

Pablo F. Hockl

Alejando J. Cagnoni

Santiago P. Méndez Huergo

Pablo A. García

Sabrina G. Gatto

Juan P. Cerliani

Diego O. Croci

Gabriel A. Rabinovich

机构：

[1] Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET),Laboratorio de Inmunopatología, Instituto de Biología y Medicina Experimental (IBYME)

[2] Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET),Laboratorio de Glicómica Funcional y Molecular, Instituto de Biología y Medicina Experimental (IBYME)

[3] Universidad Nacional de Cuyo,Facultad de Ciencias Exactas y Naturales, Instituto de Histología y Embriología de Mendoza “Dr. Mario H. Burgos”, Consejo Nacional de Investigaciones Científicas y Técnicas

[4] Universidad de Buenos Aires,Facultad de Ciencias Exactas y Naturales

来源：

Angiogenesis | 2021年 / 24卷

关键词：

Angiogenesis; Immunoregulation; Galectin-1; Neutralizing Antibody;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Galectins, a family of highly conserved β-galactoside-binding proteins, control tumor progression by modulating different hallmarks of cancer. Galectin-1 (Gal-1), a proto-type member of this family, plays essential roles in tumor angiogenesis and immunosuppression by cross-linking glycosylated receptors on the surface of endothelial and immune cells. Targeted disruption of Gal-1 suppresses tumor growth by counteracting aberrant angiogenesis and reinforcing antitumor immunity in several experimental settings. Given the multiple therapeutic benefits associated with Gal-1 blockade, several Gal-1 inhibitors, including glycan-based competitors, antagonistic peptides, aptamers and neutralizing monoclonal antibodies, have been designed and evaluated in pre-clinical tumor models. Here we report the biochemical and functional characterization of a newly developed neutralizing anti-human Gal-1 monoclonal antibody (Gal-1-mAb3), which specifically recognizes a unique epitope in Gal-1 protein and exerts both angioregulatory and immunomodulatory activities. Blockade of Gal-1 function using Gal-1-mAb3, might be relevant not only in cancer but also in other pathologic conditions characterized by aberrant angiogenesis and uncontrolled immunosuppression.

引用

页码：1 / 5

页数：4

共 56 条

[1]

Girotti MR(2020)Sweetening the hallmarks of cancer: galectins as multifunctional mediators of tumor progression J Exp Med 217 e20182041-15980

[2]

Salatino M(2006)Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy Proc Natl Acad Sci USA 103 15975-6224

[3]

Dalotto-Moreno T(2010)Tumor cells secrete galectin-1 to enhance endothelial cell activity Cancer Res 70 6216-2000

[4]

Rabinovich GA(2012)Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma J Exp Med 209 1985-3753

[5]

Thijssen VL(2008)Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells Oncogene 27 3746-758

[6]

Postel R(2014)Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors Cell 156 744-251

[7]

Brandwijk RJ(2004)Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege Cancer Cell 5 241-834

[8]

Thijssen VL(2007)Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death Nat Immunol 8 825-3102

[9]

Barkan B(2008)Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion J Immunol 180 3091-991

[10]

Shoji H(2009)Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10 Nat Immunol 10 981-1117

← 1 2 3 4 5 6 →